Contrary to these reports, IL-6−/− mice develop a mature onset obesity that can in part be reversed by replacing IL-6 [59], suggesting an important therapeutic window for IL-6 levels that may be beneficial compared to levels linked with disease. This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.